Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/03/2022* -- Results Q3 2022 -- 1.05 --
11/03/2022* 08:00 EST Earnings Call Q3 2022 -- -- --
08/03/2022 -- Results Q2 2022 1.07 1.33 -19.36%
08/03/2022 08:00 EST Earnings Call Q2 2022 -- -- --
05/04/2022 -- Results Q1 2022 1.34 1.14 17.44%
05/04/2022 08:00 EST Earnings Call Q1 2022 -- -- --
03/01/2022 -- Results Q4 2021 1.41 1.35 4.81%
03/01/2022 08:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/03/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/03/2022
Beat/Miss Upgrade
Return Since 1.39%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States.
URL https://www.horizontherapeutics.com
Investor Relations URL https://ir.horizontherapeutics.com
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Mid Cap/Blend
Next Earnings Release Nov. 03, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
68.11%
-25.33%
-9.77%
33.84%
85.26%
102.1%
47.31%
-37.00%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-20.46%
-14.15%
-22.43%
23.50%
-7.94%
20.43%
10.56%
-22.81%
9.18%
--
--
--
--
-10.18%
-78.02%
-60.38%
-67.50%
35.55%
-29.98%
-1.53%
-46.08%
-30.87%
-2.21%
16.59%
-1.93%
-13.18%
-42.14%
5.59%
-55.08%
35.65%
-11.92%
-10.96%
1.26%
As of October 06, 2022.

Profile

Edit
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States.
URL https://www.horizontherapeutics.com
Investor Relations URL https://ir.horizontherapeutics.com
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Mid Cap/Blend
Next Earnings Release Nov. 03, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
JCNIX 257.61M USD 5.99%
PJP 11.50M USD 3.74%
HQL 14.46M USD 3.69%
HQH 32.81M USD 3.54%
FBIOX 115.16M USD 2.28%
DBMYX 51.20M USD 1.85%
THQ 14.65M USD 1.65%
ATHGX 76.27M USD 1.60%
JMGQX 111.18M USD 1.43%
NUGO 36.27M USD 1.40%
XBI 75.73M USD 1.07%
FSMAX 97.35M USD 0.30%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter HZNP Tweets